Genetic Tech Spn ADR (GENE) Stock Price, Quote & News

Company Profile

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenp...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 61 3 8412 7000

Fax: 61 3 8412 7040

Website: genetype.com

Address:

321 Chapel Street, Level 1 Suite 7, Prahran, Australia

TradeHuntFish Nov. 4 at 3:49 PM

VEEE just dropped a massive news partnership with Fetch.AI to integrate autonomous AI agents into its boat marketplace platform. The daily chart looks bottomed and MAC‑D on the higher timeframes is beginning to curl bullish. With a tiny float and very low shares available to borrow, when the move comes it could catch fire. $ALIM $GENE $SLNO $BIAF

0 · Reply

TradeHuntFish Nov. 4 at 4:15 AM

VEEE just dropped a massive news partnership with Fetch.AI to integrate autonomous AI agents into its boat‑ marketplace platform. The daily chart looks bottomed and MAC‑D on the higher timeframes is beginning to curl bullish. With a tiny float and very low shares available to borrow, when the move comes it could catch fire. $ALIM $GENE $SLNO $BIAF

0 · Reply

TradeHuntFish Oct. 30 at 11:07 PM

QCLS could be the next 10 bagger just flipped its story renamed and rebranded, pivoting into quantum‑class photonic computing and crypto infrastructure. The float is tiny 2.9 M shares) and short interest is elevated, making it a classic breakout candidate. When the market notices, this could move fast. $ALIM $GENE $NLST $RGTI

1 · Reply

ChaseDeluca Oct. 30 at 10:29 PM

QCLS is literally built for explosive upside. $20+++ next week????? Quantum infrastructure + blockchain tech in a nano-float wrapper… New ticker. New story. And a chart that’s tightening by the hour. When this breaks it could go vertical. $PRST $GENE $ASST $SNSE $BYND !!!!

0 · Reply

ChaseDeluca Oct. 30 at 10:03 PM

Watch QCLS is lining up like the ones that go vertical before retail even knows what happened. Rebranded. Low float. Clean chart. And a tech narrative that checks every box traders love. It’s all about being early. $RVSN $ASST $ADTX $GENE $BYND

0 · Reply

ChaseDeluca Oct. 30 at 9:02 PM

QCLS just triggered a major transformation re branded and trading under its new ticker as it pivots into quantum class photonic/crypto infrastructure. With a float under 2 M shares and elevated short interest relative to size, the squeeze mechanics are in place. This is the kind of setup where a single catalyst or tech validation can ignite a 5×‑10× move. $BYND $GENE $BTTX $ICCH WW

0 · Reply

ChaseDeluca Oct. 17 at 9:23 PM

The next 10x play? VRME !!!! That gives upside room without intense short squeeze pressure. If technicals break, this could pick up momentum fast. $STRR $PTPI $GENE $BTTX

0 · Reply

ChaseDeluca Oct. 17 at 7:58 AM

VRME The valuation disconnect is glaring: $VRME’s P/Cash Flow is 15× while many peers trade at much higher multiples. With a golden cross forming and macro rotation into tech/AI, this could be one of the stealth names to watch….. $FTSV $GLMD $ZIVO $GENE

0 · Reply

ChaseDeluca Oct. 17 at 7:38 AM

VRME has real business brand protection + precision logistics not just hype. It’s currently underpriced vs its peers. If the chart confirms a golden cross while building strength above $1.00, we could see serious upside. $ACXP $GENE $BTTX $QH

0 · Reply

Popeye989 Oct. 14 at 3:17 PM

$GENE once upon a time you made me a lot of money. Now we part ways

0 · Reply

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIVI

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Join Genetic Technology's Exclusive Live Investor Webinar and Q&A Session on October 2

Sep 11, 2024, 8:15 AM EDT - 1 year ago

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

Jul 26, 2024, 8:00 AM EDT - 1 year ago

Genetic Technologies Strategic Restructure Driving USA Sales Growth

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

Jun 25, 2024, 8:00 AM EDT - 1 year ago

GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Join Genetic Technologies' Exclusive Live Investor Webinar and Q&A Session on June 27

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Appendix 4C & Quarterly Business Update – March 2024

Apr 22, 2024, 3:00 PM EDT - 1 year ago

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Apr 18, 2024, 12:17 PM EDT - 1 year ago

Genetic Technologies Announces $2 Million Registered Direct Offering

Apr 12, 2024, 9:00 AM EDT - 1 year ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIVI

Apr 2, 2024, 8:05 AM EDT - 1 year ago

Genetic Technologies' Digital Strategy Ignites Significant Traction in US Market

Feb 28, 2024, 8:00 AM EST - 1 year ago

GTG to launch U.S. Customer Digital Media Sales Campaign

Jan 5, 2024, 8:00 AM EST - 2 years ago

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 29, 2023, 9:00 AM EST - 2 years ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

BIVI

Dec 12, 2023, 8:00 AM EST - 2 years ago

Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change

Oct 18, 2023, 8:30 AM EDT - 2 years ago

GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment

Oct 6, 2023, 9:00 AM EDT - 2 years ago

Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

KSCP SNGX

Sep 27, 2023, 9:00 AM EDT - 2 years ago

GTG Signs Precision Medicine Pilot with Australia's Largest Private Hospital Network

Sep 15, 2023, 9:00 AM EDT - 2 years ago

Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

AREC

Sep 11, 2023, 8:30 AM EDT - 2 years ago

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

Sep 1, 2023, 10:00 AM EDT - 2 years ago

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

Sep 1, 2023, 9:00 AM EDT - 2 years ago

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

SXTP

Aug 30, 2023, 8:45 AM EDT - 2 years ago

Annual Results – Momentum Building on our Commercial Plans

Aug 18, 2023, 8:30 AM EDT - 2 years ago

Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies

CDIO

Aug 9, 2023, 12:11 AM EDT - 2 years ago

Genetic Technologies Limited (GENE) Q4 2023 Earnings Call Transcript

Jul 21, 2023, 8:00 AM EDT - 2 years ago

Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

May 3, 2023, 11:45 PM EDT - 2 years ago

Genetic Technologies Limited (GENE) Q3 2023 Earnings Call Transcript

Apr 28, 2023, 8:00 AM EDT - 2 years ago

New Publication Validates geneType for Melanoma Risk Assessment

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Back-to-back Studies Validate geneType Breast Cancer Risk Test

Feb 27, 2023, 7:56 PM EST - 2 years ago

Genetic Technologies Limited (GENE) Q2 2023 Earnings Call Transcript

Feb 7, 2023, 10:00 AM EST - 3 years ago

Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

Feb 6, 2023, 8:00 AM EST - 3 years ago

Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

Feb 3, 2023, 8:35 AM EST - 3 years ago

Genetic Technologies Announces $5 Million Registered Direct Offering

Feb 3, 2023, 8:00 AM EST - 3 years ago

GENE to Launch World's First Comprehensive Risk Test for Breast & Ovarian Cancer

Jan 30, 2023, 8:00 AM EST - 3 years ago

Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth

Dec 6, 2022, 8:00 AM EST - 3 years ago

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

Nov 6, 2022, 6:59 AM EST - 3 years ago

Genetic Technologies Limited (GENE) Q1 2023 Earnings Call Transcript

Oct 25, 2022, 9:14 AM EDT - 3 years ago

Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

Oct 13, 2022, 8:00 AM EDT - 3 years ago

Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Sep 29, 2022, 8:00 AM EDT - 3 years ago

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

Sep 2, 2022, 8:00 AM EDT - 3 years ago

Genetic Technologies Provides Update on US Operations and Payer Engagement

Aug 30, 2022, 8:00 AM EDT - 3 years ago

GENE Momentum building - a year in review

Jul 28, 2022, 8:00 AM EDT - 3 years ago

Gene achieves key milestones and growth

Jul 14, 2022, 8:00 AM EDT - 3 years ago

Completion of AffinityDNA Acquisition expanding global direct-to-consumer business

Jul 1, 2022, 8:00 AM EDT - 3 years ago

GeneType Risk Assessment Test onboarding in 16 clinics

May 16, 2022, 9:00 AM EDT - 3 years ago

Acquisition of global direct to consumer ecommerce business

Apr 20, 2022, 10:54 PM EDT - 3 years ago

Genetic Technologies Limited (GENE) CEO Simon Morriss on Q3 2022 Results - Earnings Call Transcript

Apr 8, 2022, 8:00 AM EDT - 3 years ago

Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

Feb 14, 2022, 1:01 PM EST - 4 years ago

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript

TradeHuntFish Nov. 4 at 3:49 PM

0 · Reply

TradeHuntFish Nov. 4 at 4:15 AM

0 · Reply

TradeHuntFish Oct. 30 at 11:07 PM

1 · Reply

ChaseDeluca Oct. 30 at 10:29 PM

0 · Reply

ChaseDeluca Oct. 30 at 10:03 PM

0 · Reply

ChaseDeluca Oct. 30 at 9:02 PM

0 · Reply

ChaseDeluca Oct. 17 at 9:23 PM

The next 10x play? VRME !!!! That gives upside room without intense short squeeze pressure. If technicals break, this could pick up momentum fast. $STRR $PTPI $GENE $BTTX

0 · Reply

ChaseDeluca Oct. 17 at 7:58 AM

0 · Reply

ChaseDeluca Oct. 17 at 7:38 AM

0 · Reply

Popeye989 Oct. 14 at 3:17 PM

$GENE once upon a time you made me a lot of money. Now we part ways

0 · Reply

MilsLearning Oct. 10 at 5:19 PM

$GENE Ever get bullied??? Trading stocks?? Me too!!! Well 🖕🩳🖕🔥🔥🔥🩳🖕🩳🔥

0 · Reply

TradeHuntFish Oct. 7 at 11:13 AM

watch PRHI Traders always look after the run. s giving every early signal now. 98 short squeeze score, micro float, no borrow, golden cross forming. And nobody’s loading? This is the type of setup that makes careers... $GENE $BTTX $MBRX $XELA $SERA

0 · Reply

TradeHuntFish Oct. 3 at 1:06 PM

GIPR is the kind of play that only makes sense before it takes off. Real estate backed. Undervalued. And now with serious whispers of a crypto treasury strategy that could turn this into the next multi-sector rocket. 20x–50x isn’t hype it’s math if they execute. $ZVSA $IMUX $GENE $BTTX $ACXP

0 · Reply

paulalesinis Sep. 28 at 6:10 PM

IVDA nearly $40 intrinsic value, DRONE PLAY, and is developing next-gen surveillance tech that actually works AI driven drones with real time facial recognition and weapon detection. They’re not pitching dreams they’re solving real-world problems. Still trading at the floor with virtually no retail awareness. $PRST $GENE $CING $GLMD $MTC

0 · Reply

VincentVanGoghh Sep. 19 at 4:04 AM

VRME has everything lining up: ✔️ Cash flow positive ✔️ Golden cross forming ✔️ UPS deal in place ✔️ Tight float The chart is setting up for a textbook breakout and nobody’s paying attention yet. $ZVSA $NBY $AKAN $PALI $GENE

0 · Reply

CornPops_CornHole Aug. 21 at 9:43 PM

$GENE I used to dream of GENE, but it was all a pipe.....

0 · Reply

ChaseDeluca Aug. 4 at 3:57 PM

IBG🚨 This is one of the cleanest SPAC setups in the market right now. Micro float. No dilution. Merger potential on deck. It’s quiet now but when it moves, it’ll be too late to catch the bottom. Don’t blink. $DSS $CRKN $GENE $AVTX

0 · Reply

ChaseDeluca Aug. 4 at 2:26 AM

IBG A sleeper with no dilution, no baggage, and full breakout potential. This is where smart money hunts before the crowd. $HOOK $EVAX $GENE $PHGE

1 · Reply

Metal_Health Jul. 31 at 10:30 PM

$IXHL semi-good news for stateside baggies soon they'll only dilute Australians like $GENE

0 · Reply

Love_To_Learn Jul. 2 at 10:38 AM

$SLS that uptick volume was me just now left something with your signature for markets its an old $GENE movement

2 · Reply

StocktwitsNews May. 29 at 3:15 PM

The New York Times and Amazon Strike AI Content Deal: Retail’s Yet To React $NYT $AMZN $GENE $RSPC https://stocktwits.com/news/equity/markets/new-york-times-and-amazon-strike-ai-content-deal/ch0AswDRbtM

0 · Reply

IffiTrades Apr. 30 at 4:02 PM

$GENE i remember making $16K on this stock in one day - RIP

0 · Reply

Market Cap	3.37M
Revenue (ttm)	5.03M
Net Income (ttm)	-7.88M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	22,600
Avg Vol	21,120
Day's Range	N/A - N/A
Shares Out	4.41M
Stochastic %K	50%
Beta	1.12
Analysts	Strong Buy
Price Target	$2.50